Medullary Thyroid Carcinoma

• FDA label_change · 2020-06-05
  FDA Approved: CAPRELSA — Supplemental Application (Genzyme Corporation)

  FDA reviewed and approved a supplemental application for CAPRELSA (vandetanib) submitted by Genzyme Corporation to update labeling.

• FDA label_change · 2016-05-20
  FDA Approved: COMETRIQ — Supplemental Application (Exelixis, Inc.)

  FDA approved a supplemental application for COMETRIQ (cabozantinib) submitted by Exelixis, Inc.

• FDA label_change · 2013-11-27
  FDA Approved: CAPRELSA — Supplemental Application (Genzyme Corporation)

  FDA approved a supplemental application for Caprelsa (vandetanib) submitted by Genzyme Corporation.